Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IDEAYA Biosciences (IDYA) Shares Outstanding (Diluted Average): 2021-2025

Historic Shares Outstanding (Diluted Average) for IDEAYA Biosciences (IDYA) over the last 2 years, with Jun 2025 value amounting to $88.5 million.

  • IDEAYA Biosciences' Shares Outstanding (Diluted Average) rose 13.48% to $88.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $88.5 million, marking a year-over-year increase of 13.48%. This contributed to the annual value of $81.7 million for FY2024, which is 42.00% up from last year.
  • According to the latest figures from Q2 2025, IDEAYA Biosciences' Shares Outstanding (Diluted Average) is $88.5 million, which was up 0.13% from $88.4 million recorded in Q1 2025.
  • IDEAYA Biosciences' Shares Outstanding (Diluted Average)'s 5-year high stood at $88.5 million during Q2 2025, with a 5-year trough of $35.3 million in Q4 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $76.5 million (2024), whereas its average is $72.0 million.
  • Data for IDEAYA Biosciences' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 55.28% (in 2024) over the last 5 years.
  • Over the past 5 years, IDEAYA Biosciences' Shares Outstanding (Diluted Average) (Quarterly) stood at $35.3 million in 2021, then grew by 17.57% to $41.4 million in 2022, then soared by 38.79% to $57.5 million in 2023, then surged by 42.00% to $81.7 million in 2024, then climbed by 13.48% to $88.5 million in 2025.
  • Its last three reported values are $88.5 million in Q2 2025, $88.4 million for Q1 2025, and $81.7 million during Q4 2024.